MedTrace Logo

SIII and Spontaneous Regression in Lumbar Disc Herniation

NCT07367503 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-01-26

No results posted yet for this study

Summary

This study aimed to investigate the role of the Systemic Immune-Inflammatory Index (SIII) in patients with lumbar disc herniation (LDH) and to evaluate its potential clinical relevance in relation to treatment modality.

Conditions

Interventions

OTHER

Lumbar disc herniation treatment

Lumbar disc herniation medical treatment

OTHER

Lumbar disc herniation surgery

Lumbar disc herniation surgecal treatment

Sponsors & Collaborators

  • Çanakkale Onsekiz Mart University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2023-01-30
Completion
2023-01-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07367503 on ClinicalTrials.gov